Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study
Background: Muscles from patients with cerebral palsy (CP) are often spastic and form contractures that limit the range of motion. Injections of botulinum toxin A (BTX) into the calf muscles are an important treatment for functional equinus; however, improvement in gait function is not always achiev...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.630435/full |
id |
doaj-c927e68b80974ae5b4a3e9269c6c5fd9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Weidensteiner Claudia Weidensteiner Philipp Madoerin Xeni Deligianni Xeni Deligianni Tanja Haas Oliver Bieri Oliver Bieri Tugba Akinci D'Antonoli Tugba Akinci D'Antonoli Katrin Bracht-Schweizer Jacqueline Romkes Enrico De Pieri Enrico De Pieri Francesco Santini Francesco Santini Erich Rutz Erich Rutz Reinald Brunner Reinald Brunner Meritxell Garcia |
spellingShingle |
Claudia Weidensteiner Claudia Weidensteiner Philipp Madoerin Xeni Deligianni Xeni Deligianni Tanja Haas Oliver Bieri Oliver Bieri Tugba Akinci D'Antonoli Tugba Akinci D'Antonoli Katrin Bracht-Schweizer Jacqueline Romkes Enrico De Pieri Enrico De Pieri Francesco Santini Francesco Santini Erich Rutz Erich Rutz Reinald Brunner Reinald Brunner Meritxell Garcia Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study Frontiers in Neurology cerebral palsy MRI botulinum toxin A T2 diffusion fat fraction |
author_facet |
Claudia Weidensteiner Claudia Weidensteiner Philipp Madoerin Xeni Deligianni Xeni Deligianni Tanja Haas Oliver Bieri Oliver Bieri Tugba Akinci D'Antonoli Tugba Akinci D'Antonoli Katrin Bracht-Schweizer Jacqueline Romkes Enrico De Pieri Enrico De Pieri Francesco Santini Francesco Santini Erich Rutz Erich Rutz Reinald Brunner Reinald Brunner Meritxell Garcia |
author_sort |
Claudia Weidensteiner |
title |
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study |
title_short |
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study |
title_full |
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study |
title_fullStr |
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study |
title_full_unstemmed |
Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary Study |
title_sort |
quantification and monitoring of the effect of botulinum toxin a on paretic calf muscles of children with cerebral palsy with mri: a preliminary study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2021-04-01 |
description |
Background: Muscles from patients with cerebral palsy (CP) are often spastic and form contractures that limit the range of motion. Injections of botulinum toxin A (BTX) into the calf muscles are an important treatment for functional equinus; however, improvement in gait function is not always achieved. BTX is also used to test muscle weakening for risk evaluation of muscle lengthening surgery. Our aim was to assess the effect of BTX over time on calf muscle properties in pediatric CP patients with MRI.Material and Methods: Six toe-walking CP patients (mean age 11.6 years) with indication for lengthening surgery were prospectively enrolled and received BTX injections into the gastrocnemius and soleus muscles. MRI scans at 3T of the lower legs and clinical examinations were performed pre-BTX, 6 weeks (6w), and 12 weeks (12w) post-BTX. A fat-suppressed 2D multi-spin-echo sequence was used to acquire T2 maps and for segmentation. Fat fraction maps were calculated from 3D multi-echo Dixon images. Diffusion tensor imaging (DTI) with a 2D echo-planar imaging (EPI) sequence yielded maps of the mean apparent diffusion coefficient (ADC) and of the fractional anisotropy (FA). Hyperintense regions of interest (ROIs) on the T2-weighted (T2w) images at 6w were segmented in treated muscles. Mean values of T2, fat fraction, ADC, and FA were calculated in hyperintense ROIs and in reference ROIs in non-treated muscles.Results: Hyperintensity on T2w scans and increased T2 (group mean ± standard deviation: 35 ± 1 ms pre-BTX, 45 ± 2 ms at 6w, and 44 ± 2 ms at 12w) were observed in all patients at the injection sites. The T2 increase was spatially limited to parts of the injected muscles. FA increased (0.30 ± 0.03 pre-BTX, 0.34 ± 0.02 at 6w, and 0.36 ± 0.03 at 12w) while ADC did not change in hyperintense ROIs, indicating a BTX-induced increase in extracellular space and a simultaneous decrease of muscle fiber diameter. Fat fraction showed a trend for increase at 12w. Mean values in reference ROIs remained unchanged.Conclusion: MRI showed limited spatial distribution of the BTX-induced effects in pediatric CP patients. It could be a promising non-invasive tool for future studies to test BTX treatment protocols. |
topic |
cerebral palsy MRI botulinum toxin A T2 diffusion fat fraction |
url |
https://www.frontiersin.org/articles/10.3389/fneur.2021.630435/full |
work_keys_str_mv |
AT claudiaweidensteiner quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT claudiaweidensteiner quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT philippmadoerin quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT xenideligianni quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT xenideligianni quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT tanjahaas quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT oliverbieri quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT oliverbieri quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT tugbaakincidantonoli quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT tugbaakincidantonoli quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT katrinbrachtschweizer quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT jacquelineromkes quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT enricodepieri quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT enricodepieri quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT francescosantini quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT francescosantini quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT erichrutz quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT erichrutz quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT reinaldbrunner quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT reinaldbrunner quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy AT meritxellgarcia quantificationandmonitoringoftheeffectofbotulinumtoxinaonpareticcalfmusclesofchildrenwithcerebralpalsywithmriapreliminarystudy |
_version_ |
1721525703363526656 |
spelling |
doaj-c927e68b80974ae5b4a3e9269c6c5fd92021-04-16T04:37:56ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-04-011210.3389/fneur.2021.630435630435Quantification and Monitoring of the Effect of Botulinum Toxin A on Paretic Calf Muscles of Children With Cerebral Palsy With MRI: A Preliminary StudyClaudia Weidensteiner0Claudia Weidensteiner1Philipp Madoerin2Xeni Deligianni3Xeni Deligianni4Tanja Haas5Oliver Bieri6Oliver Bieri7Tugba Akinci D'Antonoli8Tugba Akinci D'Antonoli9Katrin Bracht-Schweizer10Jacqueline Romkes11Enrico De Pieri12Enrico De Pieri13Francesco Santini14Francesco Santini15Erich Rutz16Erich Rutz17Reinald Brunner18Reinald Brunner19Meritxell Garcia20Division of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDepartment of Biomedical Engineering, University of Basel, Allschwil, SwitzerlandDivision of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDivision of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDepartment of Biomedical Engineering, University of Basel, Allschwil, SwitzerlandDivision of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDivision of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDepartment of Biomedical Engineering, University of Basel, Allschwil, SwitzerlandDepartment of Radiology, University Hospital of Basel, Basel, SwitzerlandDepartment of Radiology, University Children's Hospital Basel, Basel, SwitzerlandLaboratory for Movement Analysis, University Children's Hospital Basel, Basel, SwitzerlandLaboratory for Movement Analysis, University Children's Hospital Basel, Basel, SwitzerlandDepartment of Biomedical Engineering, University of Basel, Allschwil, SwitzerlandLaboratory for Movement Analysis, University Children's Hospital Basel, Basel, SwitzerlandDivision of Radiological Physics, Department of Radiology, University Hospital of Basel, Basel, SwitzerlandDepartment of Biomedical Engineering, University of Basel, Allschwil, SwitzerlandMurdoch Children's Research Insitute, The University of Melbourne, Pediatric Orthopedic Department, The Royal Children's Hospital, Parkville, VIC, AustraliaFaculty of Medicine, The University of Basel, Basel, SwitzerlandLaboratory for Movement Analysis, University Children's Hospital Basel, Basel, SwitzerlandDepartment of Orthopedic Surgery, University Children's Hospital Basel, Basel, SwitzerlandDepartment of Radiology, Division of Neuroradiology, University Hospital of Basel, Basel, SwitzerlandBackground: Muscles from patients with cerebral palsy (CP) are often spastic and form contractures that limit the range of motion. Injections of botulinum toxin A (BTX) into the calf muscles are an important treatment for functional equinus; however, improvement in gait function is not always achieved. BTX is also used to test muscle weakening for risk evaluation of muscle lengthening surgery. Our aim was to assess the effect of BTX over time on calf muscle properties in pediatric CP patients with MRI.Material and Methods: Six toe-walking CP patients (mean age 11.6 years) with indication for lengthening surgery were prospectively enrolled and received BTX injections into the gastrocnemius and soleus muscles. MRI scans at 3T of the lower legs and clinical examinations were performed pre-BTX, 6 weeks (6w), and 12 weeks (12w) post-BTX. A fat-suppressed 2D multi-spin-echo sequence was used to acquire T2 maps and for segmentation. Fat fraction maps were calculated from 3D multi-echo Dixon images. Diffusion tensor imaging (DTI) with a 2D echo-planar imaging (EPI) sequence yielded maps of the mean apparent diffusion coefficient (ADC) and of the fractional anisotropy (FA). Hyperintense regions of interest (ROIs) on the T2-weighted (T2w) images at 6w were segmented in treated muscles. Mean values of T2, fat fraction, ADC, and FA were calculated in hyperintense ROIs and in reference ROIs in non-treated muscles.Results: Hyperintensity on T2w scans and increased T2 (group mean ± standard deviation: 35 ± 1 ms pre-BTX, 45 ± 2 ms at 6w, and 44 ± 2 ms at 12w) were observed in all patients at the injection sites. The T2 increase was spatially limited to parts of the injected muscles. FA increased (0.30 ± 0.03 pre-BTX, 0.34 ± 0.02 at 6w, and 0.36 ± 0.03 at 12w) while ADC did not change in hyperintense ROIs, indicating a BTX-induced increase in extracellular space and a simultaneous decrease of muscle fiber diameter. Fat fraction showed a trend for increase at 12w. Mean values in reference ROIs remained unchanged.Conclusion: MRI showed limited spatial distribution of the BTX-induced effects in pediatric CP patients. It could be a promising non-invasive tool for future studies to test BTX treatment protocols.https://www.frontiersin.org/articles/10.3389/fneur.2021.630435/fullcerebral palsyMRIbotulinum toxin AT2diffusionfat fraction |